This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
To the Editor.—
We have no argument with the contention put forward by Dr. Lyon that the clinician, when employing cytotoxic agents, generally aims to produce some degree of leukopenia to ensure an optimal clinical effect. It is also unarguable that the degree of leukopenia (or thrombocytopenia) is sometimes inadvertently greater than that desired or considered safe by the clinician. If the treatment groups were otherwise comparable, then, by chance, the proportions of inadvertently excessive depression of the white cell count (or thrombocyte count), which was what was measured in our study, should have been similiar in those receiving and those not receiving allopurinol.However, chance as an explanation for our findings, at least with regard to patients who received cyclophosphamide, could confidently be ruled out. We also believe that mean leukocyte and platelet counts of 2,314/cu mm and 55,400/cu mm, respectively, can be accepted as indirect indices of bone
Allopurinol and Cytotoxic Agents. JAMA. 1974;228(11):1371–1372. doi:10.1001/jama.1974.03230360019013
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: